“Retinal Disease Pharmaceutical Sales will reach $14.85bn in 2018” says Visiongain
18 June 2018
A new report by visiongain forecasts the overall world market for treating age-related macular degeneration (AMD or ARMD), diabetic retinopathy (DR) and other disorders of the retina will reach $14.85bn in 2018. That revenue forecast and others appear in Global Macular Degeneration (AMD) and Other Retinal Diseases Drugs Industry and Market 2018-2028: Wet AMD, Dry AMD, Diabetic Retinopathy, Lucentis, Eylea, Avastin, Visudyne
Age-related macular degeneration (AMD) and other retinal diseases market is growing rapidly in pharmaceutical industry worth multi-billion-dollar sector. That updated report provides the detailed analysis and opportunities in wet AMD, dry AMD and diabetic retinopathy (DR) sector. Many pharmaceutical companies are aiming to develop more effective drugs with different mechanism of action to treat wet AMD. At present there are no drugs in the market for dry AMD, although dry age-related macular degeneration (dAMD) is more common than wet AMD (wAMD). Currently, there are many drugs in pipeline to treat dry AMD. The breakthrough in dry AMD sector for drug to get approved is expected to happen in next 5 years, visiongain estimates. The report includes analysis and revenue forecasting for top 4 drugs in wet AMD drug market. In 2015, Eylea became number one drug in retinal diseases market leaving behind Lucentis.
There are unmet needs remaining in retinal diseases sector and pharmaceutical companies are aiming to meet these needs within the next ten years. Companies seek to improve upon the standard of care (SOC) treatment for wAMD, whilst developing new therapies for dry AMD and other retinal diseases such as diabetic retinopathy (DR) and retinal vein occlusion (RVO). The retinal disease overall market is expected to keep growing for the next 10 years as current promising pipeline candidates attain approvals. The Macular Degeneration (AMD), Diabetic Retinopathy (DR) and Other Retinal Diseases: World Drug Industry and Market Forecast 2018-2028 provides an analysis of this fast-growing market in 2018, as well as forecasting the prospects for revenue growth over the period 2018-2028.
Visiongain’s lead pharmaceutical industry analyst for this report said “The AMD and other retinal diseases market is dominated by Lucentis and Eylea, which collectively represented 75.9% of revenues for the base year. Use of both Lucentis and Eylea will rapidly spread into other retinal disease indications, providing the main driver for the market in this period.
In the second half of the forecast period, growth in the wet AMD segment will increasingly be driven by uptake of new products, including new combination regimens based on blocking of multiple pathways. However, the segment is mature relative to other retinal disease markets, and Visiongain believes that growth rates will be moderate, as an increasing proportion of the patient population is addressed by new treatments.”
That updated report shows revenue forecasts to 2028 at overall world market, disease submarket, product (brand) and national level. First it gives revenue predictions to 2028 for four therapeutic submarkets at world level:
• Wet age-related macular degeneration (wAMD)
• Dry AMD (dAMD)
• Diabetic retinopathy (DR)
• Other retinal diseases (grouped forecast).
That study then predicts revenues of four prominent drugs to 2028: Lucentis, Eylea, Avastin and Visudyne.
Research, data and analyses cover activities of Roche, Novartis, Bayer, Regeneron, Allergan, Valeant and other developers, manufacturers and marketers of ophthalmic pharmaceuticals. Analyses cover leaders and other organisations for retinal medicines.
That new study also discusses R&D and commercial news and predicts revenues to 2028 in 11 leading national markets. The work analyses the United States (US), Western Europe (Italy, Spain, Germany, the UK and France), Japan and BRIC countries (Brazil, Russia, India and China).
Global Macular Degeneration (AMD) and Other Retinal Diseases Drugs Industry and Market 2018-2028 Wet AMD, Dry AMD, Diabetic Retinopathy, Lucentis, Eylea, Avastin, Visudyne adds to visiongain’s analyses on industries and markets in healthcare. Together those studies cover pharmaceuticals, diagnostics, medical devices, outsourced services and biotechnologies.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Visiongain Publishes Automation in Biopharma Industry Market Report 2023-2033
The global Automation in Biopharma Industry market was valued at US$1,784.1 million in 2022 and is projected to grow at a CAGR of 5.7% during the forecast period 2023-2033.
20 March 2023
Visiongain Publishes eClinical Solutions Market Report 2023-2033
The global eClinical Solutions market was valued at US$8.03 billion in 2022 and is projected to grow at a CAGR of 13.09% during the forecast period 2023-2033.
17 March 2023
Visiongain Publishes Therapeutic Respiratory Devices Market Report 2023-2033
The global Therapeutic Respiratory Devices market was valued at US$59.49 billion in 2022 and is projected to grow at a CAGR of 8.02% during the forecast period 2023-2033.
15 March 2023
Visiongain Publishes Regenerative Medicine Market Report 2023-2033
The global Regenerative Medicine market was valued at US$ 50.37 billion in 2022 and is projected to grow at a CAGR of 18.40% during the forecast period 2023-2033.